Hepatitis C Virus Infection
- Report Code : SMA2034961
- Published On: Sep, 2020
- Category : Healthcare & Pharma
- Pages : 33
Freedom from injecting Interferon (IFN), treating major HCV genotypes WW and betting on vaccines could bring a sea of change in the treatment of HCV infection in the future. This year the first IFN-free drug options for HCV Genotype 2/3- Gilead’s Sofosbuvir/RBV (GS-7977, PDUFA Dec. 8, 2013) is expected to be approved and launched! By 2015 launch of Gilead’s Sofosbuvir/Ledipasvir (PhIII) and AbbVie/ Enanta’s (ABT-450r/ABT-472/ABT-333) should remove the need of IFN for GT1 genotype HCV patients as well!
Tapping the Bigger Market- ROW: Gilead is moving well towards offering the best treatment options to a broader HCV pt population WW. . Genotype 1 is common in Australia, China, Taiwan and other countries in North Asia, while genotype 6 is found in Vietnam and other Southeast Asian countries. In India and Pakistan, genotype 3 is predominant, while genotype 4 is found in Middle Eastern countries such as Egypt, Saudi Arabia and Syria. A PAN genotype effective drug is what most companies are trying to sequester in their pipeline. This report comprehensively covers the current Standard of Care, its limitations and Future options for the treatment of HCV infection.
With tables and figures helping analyze worldwide Hepatitis C Virus Infection market, this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.
2.Progress in the Clinical Development of HCV drugs
•Noteworthy progress in the Oral IFN –Free combinations for Treatment of HCV
•Options for the most Challenging Patient Subtypes in HCV
•IFN intolerant and other Genotypes
•Hepatitis C Virus Prevalence in ROW
3.Competitive Landscape - IFN-Free drugs
•Gilead’s sofosbuvir/ ledipasvir
•Boehringer Ingelheim’s faldaprevir/BI 207127
•Bristol Myers’ daclatasvir/asunaprevir
4.Market Dynamics- Present and Future
•Present- Launch of Protease Inhibitors: Sunset Sooner Than Expected.
•Future- the “best-in-class IFN-free oral pill” for HCV
•ChronTech Pharma/ Inovio
•Profectus Biosciences’ HCV vaccine
•Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden
6.HCV-HIV Co infection
•Market share dynamics
•Table 1 - Data from IFN-free combinations
•Table 2 - Viral response in genotype-1 patients – IFN-combinations
•Key Abstract presented at AASLD ‘13
The Hepatitis C Virus Infection Market has been segregated into various crucial divisions including applications, types, and regions. Each market segment is intensively studied in the report contemplating its market acceptance, worthiness, demand, and growth prospects. The segmentation analysis will help the client to customize their marketing approach to have a better command of each segment and to identify the most prospective customer base.
Report Objectives / Segmentation Covered :
By Companies / players: